Case Report: MIS-C With Prominent Hepatic and Pancreatic Involvement in a Vaccinated Adolescent - A Critical Reasoning.

COVID-19 SARS-CoV-2 children hemophagocytic lymphohistiocytosis (HLH) vaccination

Journal

Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492

Informations de publication

Date de publication:
2022
Historique:
received: 15 03 2022
accepted: 27 04 2022
entrez: 2 6 2022
pubmed: 3 6 2022
medline: 3 6 2022
Statut: epublish

Résumé

Multisystem inflammatory syndrome in children (MIS-C) is a pathologic condition that has emerged during the coronavirus disease 2019 (COVID-19) pandemic. Although the epidemiological evidence of association between MIS-C and SARS-CoV-2 infection has been demonstrated, its pathogenic mechanism is still undefined. We describe the case of a 17-year old female, previously vaccinated against SARS-CoV-2, presenting with a history of asthenia, fever, cough, anorexia, abdominal pain, and vomiting. During the hospitalization, the patient developed bilateral conjunctivitis, hand vasculitis, cutaneous rash, and multiple pulmonary nodules, following by hepatitis and pancreatitis. As she reported a high-risk contact with a SARS-CoV-2 positive patient 10 days before admission, the epidemiological link and the clinical picture characterized by multi-system organ disfunction and inflammatory biomarkers increase led us to the diagnosis of MIS-C. Therefore, the patient was treated with intravenous immunoglobulin and corticosteroids, resulting in a rapid resolution of fever, cutaneous, and pulmonary involvement, while the recovery of hepatitis and pancreatitis was observed in the following weeks. This case leads to the discussion on whether SARS-CoV-2 immunized children and adolescents should be considered at risk of developing MIS-C and on their possible presentation with non-classic clinical features. Additionally, due to the increasing number of vaccinated children and adolescents, the issues resulting either from the diagnostic suspect of MIS-C or from the consequent need of an early therapeutic approach are discussed.

Identifiants

pubmed: 35652054
doi: 10.3389/fped.2022.896903
pmc: PMC9149168
doi:

Types de publication

Case Reports

Langues

eng

Pagination

896903

Informations de copyright

Copyright © 2022 Consolini, Costagliola, Spada, Colombatto, Orsini, Bonuccelli, Brunetto and Peroni.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Immun Inflamm Dis. 2021 Jun;9(2):331-339
pubmed: 33566457
J Clin Invest. 2021 May 17;131(10):
pubmed: 33705359
Front Pediatr. 2022 Apr 07;10:867968
pubmed: 35463893
Arthritis Rheumatol. 2021 Apr;73(4):e13-e29
pubmed: 33277976
Front Immunol. 2021 Feb 24;12:640093
pubmed: 33717193
N Engl J Med. 2020 Jul 23;383(4):334-346
pubmed: 32598831
BMJ Case Rep. 2021 Jul 29;14(7):
pubmed: 34326117
Clin Infect Dis. 2021 Nov 28;:
pubmed: 34849680
MMWR Morb Mortal Wkly Rep. 2022 Jan 14;71(2):52-58
pubmed: 35025852
Nat Immunol. 2021 Jan;22(1):25-31
pubmed: 33154590
Pediatrics. 2020 Dec;146(6):
pubmed: 32879033
J Pediatric Infect Dis Soc. 2021 Aug 14;10(6):706-713
pubmed: 33180935
Pediatr Infect Dis J. 2022 Mar 1;41(3):e87-e89
pubmed: 34978781
Nat Med. 2022 May;28(5):1050-1062
pubmed: 35177862
Cell. 2020 Nov 12;183(4):968-981.e7
pubmed: 32966765
BMJ Case Rep. 2022 Mar 30;15(3):
pubmed: 35354564
Pediatr Infect Dis J. 2022 Mar 1;41(3):e104-e105
pubmed: 34955521
JAMA. 2022 Jan 18;327(3):281-283
pubmed: 34928295
Nat Rev Rheumatol. 2021 Dec;17(12):731-748
pubmed: 34716418
J Pediatr. 2020 Nov;226:45-54.e1
pubmed: 32768466
ESMO Open. 2021 Dec;6(6):100283
pubmed: 34634634
J Exp Med. 2022 Feb 7;219(2):
pubmed: 34914824

Auteurs

Rita Consolini (R)

Section of Clinical and Laboratory Immunology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Giorgio Costagliola (G)

Section of Clinical and Laboratory Immunology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Erika Spada (E)

Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Piero Colombatto (P)

Division of Hepatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Alessandro Orsini (A)

Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Alice Bonuccelli (A)

Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Maurizia R Brunetto (MR)

Division of Hepatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Diego G Peroni (DG)

Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Classifications MeSH